The use of monoclonal antibody therapy in pediatric patients with COVID-19: a retrospective case series.
Bamlanivimab
COVID-19
Casirivimab
Imdevimab
Pediatric
Journal
International journal of emergency medicine
ISSN: 1865-1372
Titre abrégé: Int J Emerg Med
Pays: England
ID NLM: 101469435
Informations de publication
Date de publication:
03 Mar 2022
03 Mar 2022
Historique:
received:
19
10
2021
accepted:
17
01
2022
entrez:
4
3
2022
pubmed:
5
3
2022
medline:
5
3
2022
Statut:
epublish
Résumé
Monoclonal antibody (MCA) therapies have been utilized under emergency use authorization (EUA) for high-risk pediatric patients with mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting since late 2019. The purpose of this study was to describe the use of MCA therapy in pediatric patients in the pediatric emergency department (ED) at a large community hospital. This was a retrospective case series of high-risk pediatric patients 12 to 17 years of age who received MCA therapy in the pediatric ED between December 8, 2020 and June 3, 2021. The primary outcome was to describe the patient characteristics, clinical presentation, and safety profile of the pediatric population that received MCA therapy. The secondary outcome was to describe the incidence of hospitalizations or ED visits up to 28 days following therapy. A total of 44 patients were included in the analysis. The median number of days of symptoms was 4 with 41% of patients having symptoms between 0 and 3 days at time of MCA administration. Only one patient experienced a mild adverse event that did not require epinephrine administration. Two patients returned to the ED for reevaluation during the study follow-up period. No patients required admission within 28 days post-therapy. The administration of MCA therapy in high-risk pediatric patients in the pediatric ED was well-tolerated with subjective improvement noted in COVID-19 symptoms post-therapy. Further studies are necessary to determine the role MCA therapy may play in reducing morbidity from COVID-19 infection in high-risk pediatric patients.
Sections du résumé
BACKGROUND
BACKGROUND
Monoclonal antibody (MCA) therapies have been utilized under emergency use authorization (EUA) for high-risk pediatric patients with mild to moderate coronavirus disease 2019 (COVID-19) in the outpatient setting since late 2019. The purpose of this study was to describe the use of MCA therapy in pediatric patients in the pediatric emergency department (ED) at a large community hospital.
METHODS
METHODS
This was a retrospective case series of high-risk pediatric patients 12 to 17 years of age who received MCA therapy in the pediatric ED between December 8, 2020 and June 3, 2021. The primary outcome was to describe the patient characteristics, clinical presentation, and safety profile of the pediatric population that received MCA therapy. The secondary outcome was to describe the incidence of hospitalizations or ED visits up to 28 days following therapy.
RESULTS
RESULTS
A total of 44 patients were included in the analysis. The median number of days of symptoms was 4 with 41% of patients having symptoms between 0 and 3 days at time of MCA administration. Only one patient experienced a mild adverse event that did not require epinephrine administration. Two patients returned to the ED for reevaluation during the study follow-up period. No patients required admission within 28 days post-therapy.
CONCLUSIONS
CONCLUSIONS
The administration of MCA therapy in high-risk pediatric patients in the pediatric ED was well-tolerated with subjective improvement noted in COVID-19 symptoms post-therapy. Further studies are necessary to determine the role MCA therapy may play in reducing morbidity from COVID-19 infection in high-risk pediatric patients.
Identifiants
pubmed: 35240983
doi: 10.1186/s12245-022-00414-8
pii: 10.1186/s12245-022-00414-8
pmc: PMC8892120
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9Informations de copyright
© 2022. The Author(s).
Références
Open Forum Infect Dis. 2021 Jun 04;8(7):ofab292
pubmed: 34258319
J Pediatric Infect Dis Soc. 2021 May 28;10(5):629-634
pubmed: 33388760
Lancet. 2020 May 23;395(10237):1607-1608
pubmed: 32386565
Pediatr Infect Dis J. 2021 Dec 1;40(12):e507-e509
pubmed: 34260492
Front Cell Infect Microbiol. 2020 Nov 25;10:587269
pubmed: 33324574
Cardiovasc Pathol. 2021 Jan - Feb;50:107278
pubmed: 32889088
N Engl J Med. 2020 Jul 23;383(4):347-358
pubmed: 32598830
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
J Nurse Pract. 2021 May;17(5):528-535
pubmed: 33723483
J Korean Med Sci. 2020 May 11;35(18):e174
pubmed: 32383370
Acta Paediatr. 2020 Jun;109(6):1088-1095
pubmed: 32202343
World J Clin Cases. 2020 Nov 6;8(21):5250-5283
pubmed: 33269260
Lancet. 2020 Jun 6;395(10239):1771-1778
pubmed: 32410760
Rev Med Virol. 2021 Jan;31(1):1-10
pubmed: 32845042
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
J Gene Med. 2021 Feb;23(2):e3303
pubmed: 33305456
Lancet Child Adolesc Health. 2021 Sep;5(9):631-641
pubmed: 34273304